Clinical Trials Browser

Phase 2/3 × Interventional × Cetuximab × Clear all

NCT01810913 2026-04-15

Testing Docetaxel-Cetuximab or the Addition of an Immunotherapy Drug, Atezolizumab, to the Usual Chemotherapy and Radiation Therapy in High-Risk Head and Neck Cancer

Phase 2/3 Recruiting

613 enrolled

Head & Neck

Squamous Cell Carcinoma of Head and Neck

NCT05063552 2026-04-13

Testing the Use of Investigational Drugs Atezolizumab and/or Bevacizumab With or Without Standard Chemotherapy in the Second-Line Treatment of Advanced-Stage Head and Neck Cancers

Phase 2/3 Active not recruiting

430 enrolled

Head & Neck

Lymphoid Interstitial Pneumonia, Squamous Cell Carcinoma of Head and Neck, Nasopharyngeal Carcinoma, Carcinoma, Hypopharyngeal Neoplasms, Laryngeal Neoplasms, Mouth Neoplasms, Oropharyngeal Neoplasms

NCT02438722 2026-02-06

S1403, Afatinib Dimaleate With or Without Cetuximab in Treating Patients With Newly Diagnosed Stage IV or Recurrent, EGFR Mutation Positive Non-small Cell Lung Cancer

Phase 2/3 Active not recruiting

174 enrolled 18 charts

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT03258554 2026-02-06

Radiation Therapy With Durvalumab or Cetuximab in Treating Patients With Locoregionally Advanced Head and Neck Cancer Who Cannot Take Cisplatin

Phase 2/3 Completed

196 enrolled 31 charts

Head & Neck

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Hypopharyngeal Neoplasms, Laryngeal Neoplasms, Mouth Neoplasms, Oropharyngeal Neoplasms

NCT05710406 2026-01-26

Testing the Use of BRAF-Targeted Therapy After Surgery and Usual Chemotherapy for BRAF-Mutated Colon Cancer

Phase 2/3 Active not recruiting

1 enrolled

Gastrointestinal

Colonic Neoplasms

NCT02942706 2021-04-30

Cetuximab Maintenance Treatment Versus Continuation After Induction Therapy in mCRC

Phase 2/3 Unknown

200 enrolled

Gastrointestinal

Colorectal Neoplasms

NCT03031444 2021-02-01

PARECEC

Phase 2/3 Completed

135 enrolled

Gastrointestinal

Neoplasm Metastasis, Colorectal Neoplasms

NCT02978313 2016-11-30

Cetuximab Monotherapy Maintenance Treatment in mCRC

Phase 2/3 Unknown

500 enrolled

Gastrointestinal

Colorectal Neoplasms

NCT00975897 2013-12-19

Study of Tumor Tissue Testing in Selecting Treatment for Patients With Metastatic or Locally Advanced Colorectal Cancer

Phase 2/3 Completed

3,240 enrolled

Gastrointestinal

Colonic Neoplasms, Rectal Neoplasms, Colorectal Neoplasms

NCT00509561 2012-12-18

Cisplatin, Capecitabine, and Radiation Therapy With or Without Cetuximab in Treating Patients With Esophageal Cancer

Phase 2/3 Unknown

259 enrolled

Gastrointestinal

Adenocarcinoma Of Esophagus, Esophageal Squamous Cell Carcinoma, Esophageal Neoplasms